The drama and uncertainty around Novo Nordisk and Hims & Hers Health might finally be ending.

Hims & Hers Health, Inc. HIMS trended on Wednesday after the company outlined an expanded weight-management push tied to ...

These companies are benefiting from a tidal wave of demand for new weight-loss drugs.

Telehealth company Hims & Hers Health, known for its weight-loss drug business, is promising it can diversify away from its ...

March 9 (Reuters) - Hims & Hers' shares were up over 40% on Monday, after Novo Nordisk agreed to sell its blockbuster Wegovy ...

HIMS stock soars on a settlement and partnership with Novo Nordisk. But Hims & Hers shares are unlikely to sustain these ...

Two healthcare names are drawing fresh analyst attention this week as Wall Street recalibrates around a landmark GLP-1 truce and a fertility benefits company navigating a murky 2026 outlook. Barclays ...

Novo Nordisk will sell Wegovy and Ozempic drugs through the telehealth company Hims & Hers.

Hims & Hers Health (NYSE:HIMS) looked like a fallen growth star earlier this year. The telehealth platform was hammered by the FDA’s aggressive crackdown on compounded GLP-1 drugs, complete with ...